Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm1

Husebye, Einar; Tøn, Hege; Johne, Berit

doi:10.1111/j.1572-0241.2001.04126.x

Cited by 31 publications

(21 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, children exhibiting poor growth may have higher intestinal permeability, leading to a higher FC concentration. In this study, the wide range of inter- and intra-individual variation in calprotectin excretion in feces may also be explained by normal biological variability, with day-to-day variations as have been described previously in adults and children [ 30 , 47 , 48 ].…”

Section: Discussionsupporting

confidence: 56%

Fecal Calprotectin Concentrations in Healthy Children Aged 1-18 Months

Geng

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

ObjectiveFecal calprotectin (FC) is an established biomarker of gut inflammation. The aim of this study was to evaluate FC concentrations in healthy children between 1 and 18 months of age.MethodsHealthy children aged 1-18 months were enrolled in this study at the Department of Children's Health Care in Shanghai, China. Children’s stool samples were collected and analyzed, and FC concentration was determined using a commercially available enzyme-linked immunosorbent assay (ELISA). The children's weights and lengths were measured. Parents were asked to complete a brief questionnaire regarding several clinical and sociodemographic factors.ResultsThe FC concentrations were unevenly distributed; the median FC concentration was 174.3 μg/g (range: 6.0-1097.7 μg/g) or 2.241 log10 μg/g (range: 0.775-3.041 log10 μg/g) for all 288 children. The children were divided into several age groups: 1-3 months, 3-6 months, 6-9 months, 9-12 months and 12-18 months. The median FC concentrations for these age groups were 375.2 μg/g (2.574 log10 μg/g), 217.9 μg/g (2.338 log10 μg/g), 127.7 μg/g (2.106 log10 μg/g), 96.1 μg/g (1.983 log10 μg/g) and 104.2 μg/g (2.016 log10 μg/g), respectively. A significant correlation between age and FC concentration was found (r=-0.490, p<0.001). A simple correlation analysis of weight-for-length Z-scores or weight-for-age Z-scores vs. FC concentrations showed that these variables were negatively correlated (Spearman’s rho=-0.287, p<0.001; Spearman’s rho=-0.243, p<0.001, respectively).ConclusionsThe FC levels of children aged 1-18 months exhibit a downward trend with increasing age and are greater than the normal levels observed in healthy adults. In healthy children aged <6 months, FC levels are high. In children aged 6-18 months, FC concentrations are relatively low but are still higher than those of children aged >4 years.

show abstract

Section: Discussionsupporting

confidence: 56%

Fecal Calprotectin Concentrations in Healthy Children Aged 1-18 Months

Geng

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Day-to-day variation of FC was demonstrated by Husebay et al[ 13 ] in patients without colonic inflammation or neoplasm and confirmed by Moum et al[ 14 ], in patients with mild-to-moderate active CD, where significant differences in 63 pairs of stool samples collected in 2 consecutive days were found. A lower variability was observed in fecal samples collected for 3 d from 93 CD patients in clinical remission[ 15 ].…”

Section: Pitfalls In Fc Assessmentmentioning

confidence: 65%

From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting

Mumolo

Bertani

Ceccarelli

et al. 2018

WJG

142

116

View full text Add to dashboard Cite

Fecal calprotectin (FC) has emerged as one of the most useful tools for clinical management of inflammatory bowel diseases (IBD). Many different methods of assessment have been developed and different cut-offs have been suggested for different clinical settings. We carried out a comprehensive literature review of the most relevant FC-related topics: the role of FC in discriminating between IBD and irritable bowel syndrome (IBS) and its use in managing IBD patients In patients with intestinal symptoms, due to the high negative predictive value a normal FC level reliably rules out active IBD. In IBD patients a correlation with both mucosal healing and histology was found, and there is increasing evidence that FC assessment can be helpful in monitoring disease activity and response to therapy as well as in predicting relapse, post-operative recurrence or pouchitis. Recently, its use in the context of a treat-to-target approach led to a better outcome than clinically-based therapy adjustment in patients with early Crohn’s disease. In conclusion, FC measurement represents a cheap, safe and reliable test, easy to perform and with a good reproducibility. The main concerns are still related to the choice of the optimal cut-off, both for differentiating IBD from IBS, and for the management of IBD patients.

show abstract

“…From approximately that age up to 17-year-old healthy children, calprotectin concentrations seem to be similar to that of healthy adults [15,16]. In adults, a day-to-day variation in calprotectin excretion in serial samples has been demonstrated both in IBD patients and in controls [17,18]. However, a recent study in a large cohort of clinically quiescent CD patients showed a low day-to-day variation in calprotectin concentrations obtained on 3 consecutive days [19].…”

Section: Calprotectinmentioning

confidence: 99%

Diagnostics and Prognostics of Inflammatory Bowel Disease with Fecal Neutrophil-Derived Biomarkers Calprotectin and Lactoferrin

Sipponen

2013

Dig Dis

View full text Add to dashboard Cite

Crohn's disease (CD), ulcerative colitis (UC), and colitis unclassified, collectively defined as inflammatory bowel disease (IBD), are the consequence of chronic inflammatory reactions in the gastrointestinal tissue. Endoscopy with biopsies is the mainstay in the diagnosis of this inflammation and is also important in the assessment of disease activity and monitoring of treatment. Furthermore, mucosal healing is increasingly becoming a therapeutic target for treatment of IBD and the golden standard of assessing it is endoscopy. However, due to the costs, invasiveness, and to limited endoscopic capacity, the need is strong for reliable surrogate markers of intestinal inflammation. Bowel contents, being in close contact with intestinal mucosa, can take up molecules that are measurable from stool samples and thus can serve as markers of inflammation. The fecal neutrophil-derived biomarkers, especially calprotectin and lactoferrin, have several features of an ideal test for detecting intestinal inflammation: they are noninvasive, simple, and low in cost. The utility of these biomarkers in distinguishing IBD from noninflammatory conditions such as irritable bowel syndrome is well documented. They correlate closely with endoscopic activity both in CD and UC. They allow serial monitoring of disease activity and of treatment success, and can even serve in predicting clinical relapse in unsymptomatic patients or sustained remission after induction with TNF-α-blocking agents. In this review an overview will be given to the role of fecal neutrophil-derived biomarkers calprotectin and lactoferrin in diagnostics and prognostics of IBD.

show abstract

Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm1

Cited by 31 publications

References 9 publications

Fecal Calprotectin Concentrations in Healthy Children Aged 1-18 Months

Fecal Calprotectin Concentrations in Healthy Children Aged 1-18 Months

From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting

Diagnostics and Prognostics of Inflammatory Bowel Disease with Fecal Neutrophil-Derived Biomarkers Calprotectin and Lactoferrin

Contact Info

Product

Resources

About